Follow-up after VA ablation
Survival and recurrence-free survival are shown in Figure 1Aand 1B, respectively. The overall recurrence-free rate at 1-year for the whole cohort was 72%; 67% in the VT group vs. 78% in the PVC group.
During a median follow-up of 478 days (IQR 121, 894) after VA ablation, 5 patients died in the VT group, whereas no patients in the PVC group died. There were no procedure or arrhythmia-related deaths. Two patients died from progressive heart failure, one patient died from respiratory failure and the cause of death was unknown in 2 patients.
There was no significant difference in survival after VA ablation between patients with a history of CAD or without history of CAD (Log rank P=0.82) (Figure 2A ); however, there was a trend that patients without history of CAD had lower recurrence-free survival than those with CAD (Log rank P=0.06) (Figure 2B ).